Announcements Trials
Browse Landscape

Phase

Phase NA 34Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Endocrine 1

Conditions

Breast Neoplasms 320Leukemia, Myeloid, Acute 266Multiple Myeloma 227Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 202Neoplasms 196Lymphoma 191Colorectal Neoplasms 184Melanoma 179Leukemia 170Recurrence 164Pancreatic Neoplasms 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 160Lung Neoplasms 150Glioblastoma 134Neoplasm Metastasis 132Lymphoma, Non-Hodgkin 128Ovarian Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 120Myelodysplastic Syndromes 117Lymphoma, Large B-Cell, Diffuse 110Lymphoma, Mantle-Cell 108Carcinoma, Hepatocellular 103Lymphoma, Follicular 99Stomach Neoplasms 96Carcinoma, Renal Cell 89Hodgkin Disease 88Brain Neoplasms 88Sarcoma 84Burkitt Lymphoma 75

Interventions

ixazomib 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Alzheimer Disease × Clear all
NCT03236792 2022-09-29

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
28 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT02072252 2017-08-17

TODAY!

Northwestern University

Phase 1/2 Withdrawn
Endocrine

Generalized Anxiety Disorder, Alzheimer Disease, Anxiety Disorders, Bisexuality, Depression, Homosexuality, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡